Key Market Indicator:
In this news category you will find information from and about companies, organizations, institutions, products of all kinds and in a broad spectrum. To get a quick overview of current trends and developments, it's worth visiting daily.
DE000A3H2184
Mon, 15.08.2022
Epigenomics AG
Epigenomics AG: Notice of Loss pursuant to Sec. 92 par. 1 AktG
Berlin, August 15, 2022 - The Executive Board of Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY; the "Company") notifies that according to its best judgment a cumulative loss of more than half of the nominal share capital of the Company has been incurred. This anticipated [ … ]
Mon, 15.08.2022
Epigenomics AG
Epigenomics AG: Notice of Loss pursuant to Sec. 92 par. 1 AktG
Berlin, August 15, 2022 - The Executive Board of Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY; the "Company") notifies that according to its best judgment a cumulative loss of more than half of the nominal share capital of the Company has been incurred. This anticipated [ … ]
Wed, 10.08.2022
Epigenomics AG
Epigenomics AG Reports Financial Results for the First Six Months of 2022
Berlin (Germany) and San Diego, CA (U.S.A.), August 10, 2022 - Epigenomics AG (FSE: ECX, OTCQX: EPGNY, the "Company") today reported financial results (IFRS, unaudited) for the second quarter and first half of 2022.
Key figures
Total revenue increased slightly from EUR 22 [ … ]
Wed, 10.08.2022
Epigenomics AG
Epigenomics AG Reports Financial Results for the First Six Months of 2022
Berlin (Germany) and San Diego, CA (U.S.A.), August 10, 2022 - Epigenomics AG (FSE: ECX, OTCQX: EPGNY, the "Company") today reported financial results (IFRS, unaudited) for the second quarter and first half of 2022.
Key figures
Total revenue increased slightly from EUR 22 [ … ]
Wed, 11.05.2022
Epigenomics AG
Epigenomics AG Reports Financial Results for the First Quarter of 2022
Berlin (Germany) and San Diego, CA (U.S.A.), May 11, 2022 - Epigenomics AG (FSE: ECX, OTCQX: EPGNY, the "Company") today reported financial results (IFRS, unaudited) for the first three months of 2022.
Financial key figures
Revenues in the first quarter 2022 increased slight [ … ]
Thu, 24.03.2022
Epigenomics AG
Epigenomics AG Reports Financial Results for Fiscal Year 2021
Total revenue of EUR 6.2 million, adjusted EBITDA of EUR -1.8 million
FDA clinical trial for Epi proColon "Next Gen" expected to start with patient enrollment this summer and to take two years to complete; publication of preliminary data is anticipated
Company evaluating multiple fi [ … ]
Mon, 24.01.2022
Epigenomics AG
Supervisory Board of Epigenomics AG Retains Greg Hamilton as Chief Executive Officer Through Development of Epi proColon "Next-Gen" Colorectal Cancer Screening Test
Greg Hamilton retained as CEO through 2025
Appointment underscores Epigenomics' commitment to the company's enhanced blood-based colorectal cancer screening test, Epi proColon "Next-G [ … ]
Tue, 14.12.2021
Epigenomics AG
Supervisory Board of Epigenomics AG appoints Jens Ravens as Chief Financial Officer
Jens Ravens is an internationally experienced leader with in-depth experience in Controlling, Finance, M&A, IT, Legal, and Human Resources
New Chief Financial Officer to join Epigenomics on February 1, 2022
Berlin (Germany) and San Diego, CA (U.S.A.), Decembe [ … ]
Thu, 18.11.2021
Epigenomics AG
Supervisory Board of Epigenomics AG Appoints Dr. Andrew Lukowiak as President and Chief Scientific Officer
Dr. Andrew Lukowiak is a proven senior executive with deep technology and development expertise
Appointment underscores Epigenomics' commitment to the opportunity for Epi proColon "Next-Gen", the company's enhanced blood-based colorectal ca [ … ]
Wed, 10.11.2021
Epigenomics AG
Epigenomics AG publishes financial results for the first nine months 2021
Berlin (Germany) and San Diego, CA (U.S.A.), November 10, 2021 - Epigenomics AG (FSE: ECX, OTCQX: EPGNY, the "Company") today reported financial results (IFRS, unaudited) for the first nine months of 2021.
9M 2021 FINANCIAL RESULTS
Total revenue in the first nine months o [ … ]